# TISSUE CROSS-REACTIVITY STUDY OF A HUMAN ANTIBODY

> **NIH NIH N02** · SRI INTERNATIONAL · 2021 · $107,538

## Abstract

The test agent is being considered for development as an anticancer therapeutic. 
The objective of this task was to obtain a source of tissue or cells for in vitro evaluations of toxicity. 
The information obtained from this investigation was used to identify drugs with the potential to treat cancer.

## Key facts

- **NIH application ID:** 10474740
- **Project number:** 261201600017I-0-759102100001-1
- **Recipient organization:** SRI INTERNATIONAL
- **Principal Investigator:** JON MIRSALIS
- **Activity code:** N02 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $107,538
- **Award type:** —
- **Project period:** 2021-04-09 → 2022-04-08

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10474740

## Citation

> US National Institutes of Health, RePORTER application 10474740, TISSUE CROSS-REACTIVITY STUDY OF A HUMAN ANTIBODY (261201600017I-0-759102100001-1). Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/grant/nih/10474740. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*